Rhythm CFO exercises options for 6,099 shares

Rhythm Pharmaceuticals' Chief Financial Officer Hunter C. Smith acquired shares through an option exercise.

Accepted by SEC EDGAR 03/02/2026 - 08:56 PM EST

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Rhythm Pharmaceuticals' Chief Financial Officer Hunter C. Smith acquired shares through an option exercise. On March 2, 2026, Smith exercised stock options for 6,099 options, which converted into 6,099 shares of common stock at an exercise price of $6.80 per share.

After these transactions, Smith directly held 91,401 stock options and 116,611 shares of common stock. The filing notes that the options involved in this exercise were fully vested.

Insider Trade Summary

6,099 shares exercised/converted

Exercise 2 txns

Insider Smith Hunter C

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy)	6,099	$0.00	$0.00
Exercise	Common Stock	6,099	$6.80	$41K

Holdings After Transaction: Stock Options (Right to Buy) — 91,401 contracts (Direct); Common Stock — 116,611 shares (Direct)

Footnotes (1)

F1. The options are fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Rhythm Pharmaceuticals (RYTM) report for Hunter C. Smith?

Rhythm Pharmaceuticals reported that CFO Hunter C. Smith exercised stock options, acquiring 6,099 shares of common stock. The transaction occurred on March 2, 2026 and reflects a derivative exercise, not an open-market stock purchase or sale.

How many Rhythm Pharmaceuticals (RYTM) shares did the CFO acquire in this Form 4?

The CFO acquired 6,099 shares of Rhythm Pharmaceuticals common stock through an option exercise. An equal number of stock options were converted, reflecting a derivative exercise at a stated price of $6.80 per share, rather than a typical market buy transaction.

What was Hunter C. Smith’s ownership in Rhythm Pharmaceuticals (RYTM) after the reported transactions?

After the transactions, Hunter C. Smith directly held 116,611 shares of Rhythm Pharmaceuticals common stock and 91,401 stock options. These figures represent his updated direct ownership following the March 2, 2026 option exercise and resulting share acquisition.

Were the options exercised by the Rhythm Pharmaceuticals (RYTM) CFO fully vested?

Yes, the Form 4 notes that the stock options exercised by the Rhythm Pharmaceuticals CFO were fully vested. This means the rights to exercise those options had fully accrued before conversion into 6,099 shares of common stock on March 2, 2026.

Did the Rhythm Pharmaceuticals (RYTM) Form 4 show any open-market stock sales or purchases?

The Form 4 does not report open-market buys or sells. Instead, it shows a derivative transaction where 6,099 stock options were exercised and converted into 6,099 shares of common stock at a stated exercise price of $6.80 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Hunter C

(Last)

(First)

(Middle)

C/O RHYTHM PHARMACEUTICALS, INC.

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON

02116

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/02/2026		M		6,099	A	$6.8	116,611	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)	$6.8	03/02/2026		M			6,099	⁽¹⁾	02/08/2032	Common Stock	6,099	$0	91,401	D

Explanation of Responses:

1. The options are fully vested.

	/s/ Stephen Vander Stoep, attorney-in-fact for Hunter C. Smith	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR